Sulfathiazole

CHEMBL437 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
255.3 g/mol
LogP
0.1
Phase
4

Sulfathiazole is a short-acting sulfonamide antibiotic used in combination topical preparations for vaginal infections (combined with sulfacetamide and sulfabenzamide) and historically for systemic bacterial infections before development of more effective agents. It inhibits dihydropteroate synthase in susceptible bacteria, blocking folate synthesis. Its combination use in triple sulfonamide vaginal preparations exploits synergistic antibacterial coverage against multiple pathogens.

分子量

255.3000 g/mol

LogP

0.10

TPSA

122.00 Ų

リピンスキーの五則

適合

作用機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

InChI

InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)

Molecular Formula

C9H9N3O2S2

HBD / HBA

2 / 6

回転可能結合数

3

重原子数

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Sulfathiazole is a short-acting sulfonamide antibiotic used in combination topical preparations for vaginal infections (combined with sulfacetamide and sulfabenzamide) and historically for systemic bacterial infections before development of more effective agents. It inhibits dihydropteroate synthase in susceptible bacteria, blocking folate synthesis. Its combination use in triple sulfonamide vaginal preparations exploits synergistic antibacterial coverage against multiple pathogens.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Sulfathiazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL437. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5340. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.